Exciting Advances in Endocrine Therapies for Breast Cancer! 🌟
In a recent OncLive Peer Exchange, our very own Dr. Gregory Vidal shares a panel with Dr. Komal Jhaveri, Dr. Timothy Pluard, Dr. Aditya Bardia, and Dr. VK Gadi to discuss the promising landscape of novel endocrine drugs.
Discussion highlights include:
– The emergence of selective estrogen receptor degraders (SERDs) and other innovative therapies
– The importance of multiple targeting approaches, including oral SERDs and PROTACs like ARV-471
– The potential impact on specific mutations like Y537S and consider toxicity profiles when selecting treatments
– The need for more biomarkers and advanced testing methods, considering cost implications and the evolving nature of clinical trials
Click here to watch the full video discussion.
